Clinical Trial Update: First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients. [Phase 3]

View source ↗

Summary

A Phase 3 trial is investigating upfront immunotherapy-based standard of care combined with local ablative therapies for oligometastatic non-small cell lung can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Oligometastatic Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Status: RECRUITING